Retinal Research

Featured Studies for Recruitment

Ophthotech OPH2003B – A phase 2/3 randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreous administration of Zimura (Anti-C5 Aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration – See Study @ ClinicalTrials.gov

Opthea OPT302-1002 – A Dose-Ranging Study of Intravitreal OPT-302 in Combination with Ranibizumab, Compared to Ranibizumab Alone, in Participants with Neovascular Age-Related Macular Degeneration – See Study @ ClincalTrials.gov

Santhera SNT-IV-005 – External Natural History Controlled, open-label intervention study to assess the efficacy and safety of long-term treatment with Raxone in Leber Hereditary Optic NeuropathySee Study @ ClinicalTrials.gov

Aldeyra ADX-102 (Non-Infectious Anterior Uveitis) – A Phase 3 Randomized, Double-Masked, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Topical Ocular Formulation in Subjects with Non-Infectious Anterior Uveitis. See Study @ ClinicalTrials.gov

VisionCare IMT-PAS-01A prospective, multicenter post-approval study of VisionCare’s Implantable Miniature Telescope in patients with bilateral severe to profound central vision impairment associated with end-stage age-related macular degeneration.

Enrolling Studies

Neovascular Macular Degeneration/Wet or Dry Macular Degeneration – AMD is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small spot near the center of the retina and the part of the eye needed for sharp, central vision, which lets us see objects that are straight ahead. In some people, AMD advances so slowly that vision loss does not occur for a long time. In others, the disease progresses faster and may lead to a loss of vision in one or both eyes.

Opthea OPT302-1002 – A Dose-Ranging Study of Intravitreal OPT-302 in Combination with Ranibizumab, Compared to Ranibizumab Alone, in Participants with Neovascular Age-Related Macular Degeneration – See Study @ ClincalTrials.gov

Ophthotech OPH2003B – A phase 2/3 randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreous administration of Zimura (Anti-C5 Aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration – See Study @ ClinicalTrials.gov

VisionCare IMT-PAS-01 – A prospective, multicenter post-approval study of VisionCare’s Implantable Miniature Telescope in patients with bilateral severe to profound central vision impairment associated with end-stage age-related macular degeneration.

IMT-TES 2016 – A Prospective, Multicenter Clinical Trial of the Implantable Miniature Telescope in Pseudophakic Eyes with Central Vision Impairment associated with End-Stage Macular Degeneration.

ALLEGRO DRY AMD 101 – Randomized, Controlled, Double-Masked, Crossover Clinical Trial is designed to Evaluate the Safety and Exploratory Efficacy of 1.0 mg Luminate (ALG-1001) as a Treatment for Non-Exudative Macular Degeneration

Retinal Vein Occlusion – Retinal vein occlusion (RVO) is a common vascular disorder of the retina and one of the most common causes of vision loss worldwide. Specifically, it is the second most common cause of blindness from retinal vascular disease after diabetic retinopathy. RVO is classified according to where the occlusion is located. Occlusion of the central retinal vein at the level of the optic nerve is referred to as central retinal vein occlusion (CRVO). Obstruction at any more distal branch of the retinal vein is referred to as branch retinal vein occlusion (BRVO).

Clearside Topaz CLS1003-302 – A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal anti-VEGF agent in subjects with retinal vien occlucion – See Study @ ClinicalTrials.gov

ORA (TLC399A2002) – A phase IIA trial of an intravitreal liposomal form of steriod in patients with Macular Edema due to central retinal vein occlusion or branch retinal vein occlusion. A double-masked, randomized trial to evaluate efficacy and tolerability

Uveitis – Uveitis is a general term describing a group of inflammatory diseases that produces swelling and destroys eye tissues. The uvea is the middle layer of the eye and includes the iris, choroid, and ciliary body.

Aldeyra ADX-102 (Non-Infectious Anterior Uveitis) – A Phase 3 Randomized, Double-Masked, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Topical Ocular Formulation in Subjects with Non-Infectious Anterior Uveitis). See Study @ ClinicalTrials.gov

Diabetic Macular Edema/Diabetic Retinopathy – Diabetic Macular Edema (DME) is an accumulation of fluid in the macula—part of the retina that controls our most detailed vision abilities—due to leaking blood vessels. In order to develop DME, you must first have diabetic retinopathy. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment. Left untreated, these blood vessels begin to build up the pressure in the eye and leak fluid, causing DME.

Opthea 302-1003 – Phase 1B/2A study of OPT302 in combination with Aflibercept for Persistent Central-Involved Diabetic Macular Edema – See Study @ ClinicalTrials.gov

Thrombogenics THR-149-001 – a phase 1, open-label, multicenter, dose escalation study to evaluate the safety of a single intravitreal injection of THR-149 for the treatment of diabetic macular edema (DME) 3-4 month study – See Study @ ClinicalTrials.gov

Leber’s Hereditary Optic Neuropathy

Santhera SNT-IV-005 – External Natural History Controlled, open-label intervention study to assess the efficacy and safety of long-term treatment with Raxone in Leber’s Hereditary Optic Neuropathy – See Study @ ClinicalTrials.gov

Stargardt’s Disease

Ophthotech OPH2005 – A Phase 2b Randomized, Double-Masked, Controlled Trial to Establish the Saftey and Efficacy of Zimura (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease – See Study @ ClinicalTrials.gov

Learn More

Retinal Research Institute